There were no changes to the KraneShares models this week. This week we highlight the Chinese HealthCare Sector (KURE).
There were no changes to the KraneShares models this week.
Last week, we were forced to do a special evaluation of KraneShares Tactical Emerging Markets Model due to the closing of the KraneShares MSCI All China Index ETF (KALL), which had been a holding in the strategy. The fund was removed from the inventory alongside a special evaluation that took place after the market close on Wednesday (5/21/25). The former allocation toward KALL in the Model was disseminated across the remaining holdings in an equal-weighted fashion, as the portfolio continues to target a maximum overweight toward Chinese equities. Those with questions on the fund closing can contact KraneShares at info@kraneshares.com. Reach out to us with any questions on the model at NDWsupport@nasdaq.com.
This past week was a relatively quiet week for China. The 90-day temporary pause on sky-high tariffs between China and the United States is still in effect, as investors continue to monitor for the latest updates (source:apnews.com). Although equities struggled slightly over the past week amid China’s Central bank cutting the 1-Year Loan Prime Rate to 3.0% from 3.1%, the healthcare sector has shown some signs of strength. Last week, Jiangsu Hengrui Pharmaceuticals gained over 25% when it IPO’ed, raising $1.3 billion dollars from investors and helping push the Chinese healthcare sector to over 3% last week (source:chinalastnight). This is a sign of Hong Kong’s strength as more companies continue to have successful IPOs in the exchange.
The KraneShares MSCI All China Health Care Index ETF (KURE) broke a double top at $160 and reversed into a positive trend for the first time since late 2024. This marks the fund’s third consecutive buy signal and is up over 13% year-to-date. KURE has a strong fund score of 4.73 and an even more impressive score direction of 4.25. Long term, the fund faces resistance between $16-$16.50, with its next level of resistance not seen until $20. Initial support is at $15, with additional support at $13.75.
